Summary of Key Points Core Viewpoint - 嘉和美康 has experienced a significant decline in revenue and net profit for the first nine months of 2025, indicating potential challenges in its business operations and market position [2]. Group 1: Financial Performance - For the period from January to September 2025, 嘉和美康 reported operating revenue of 330 million yuan, a year-on-year decrease of 30.67% [2]. - The company recorded a net profit attributable to shareholders of -174 million yuan, representing a year-on-year decrease of 320.68% [2]. Group 2: Shareholder and Market Activity - As of September 30, 2025, 嘉和美康 had 7,592 shareholders, an increase of 1.84% compared to the previous period [2]. - The average number of circulating shares per shareholder was 18,122, a decrease of 1.80% from the previous period [2]. - On November 11, 嘉和美康's stock price fell by 0.59%, with a trading volume of 60.01 million yuan [1]. Group 3: Financing and Margin Trading - On November 11, 嘉和美康 had a financing buy-in amount of 8.86 million yuan and a financing repayment of 9.05 million yuan, resulting in a net financing buy of -185,800 yuan [1]. - The total margin trading balance for 嘉和美康 was 187 million yuan, accounting for 5.42% of its market capitalization, which is above the 80th percentile of the past year [1]. - The company had no short selling activity on November 11, with a short selling balance of 0 [1]. Group 4: Business Overview - 嘉和美康 (Beijing Jiahe Meikang Technology Co., Ltd.) was established on March 3, 2006, and went public on December 14, 2021 [1]. - The company's main business involves the research and industrialization of medical information software, with revenue composition as follows: software development and technical services (42.39%), self-developed software sales (37.64%), purchased software and hardware sales (19.86%), and other service sales (0.11%) [1].

融资融券余额1.87亿元，较昨日上涨0.37%。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-10 | 1.87亿 | 69.55万 | 0.37% | | 2025-11-07 | 1.87亿 | 7.41万 | 0.04% | | 2025-11-06 | 1.87亿 | 611.95万 | 3.39% | | 2025-11-05 | 1.81亿 | 272.51万 | 1.53% | | 2025-11-04 | 1.78亿 | -556.15万 | -3.03% | 证券之星消息，11月10日，嘉和美康（688246）融资买入683.41万元，融资偿还613.87万元，融资净买 入69.55万元，融资余额1.87亿元，近3个交易日已连续净买入累计688.9万元。 | 交易日 | 融资净买入(元) | | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | --- | | 2025-11-10 | | 69.55万 | 1.87亿 | 5.39% | | 2025-1 ...

Market Overview - On November 7, the AI medical sector declined by 0.83%, with Madi Technology leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - Notable gainers included: - Chuangyi Huikang (300451) with a closing price of 5.18, up 7.02% on a trading volume of 1.3279 million shares and a turnover of 674 million yuan [1] - Other stocks showed minor fluctuations, with some experiencing slight declines: - Madi Technology (603990) closed at 16.98, down 4.12% with a trading volume of 257,500 shares and a turnover of 442 million yuan [2] Capital Flow - The AI medical sector saw a net outflow of 476 million yuan from institutional investors, while retail investors contributed a net inflow of 304 million yuan [2] - The capital flow for individual stocks indicated varied investor sentiment, with some stocks experiencing significant net inflows from retail investors despite overall sector declines [3]

Core Viewpoint - Jiahe Meikang (688246.SH) is currently trading at 24.89 yuan, reflecting a decline of 2.81% and is in a state of breaking its initial public offering price [1] Group 1: Company Overview - Jiahe Meikang was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 14, 2021, with an initial offering price of 39.50 yuan per share [1] - The company issued a total of 34.4694 million shares during its IPO, raising a total of 1.362 billion yuan [1] - After deducting issuance costs, the net proceeds from the IPO amounted to 1.24 billion yuan, which was 490 million yuan more than the original plan [1] Group 2: Fundraising and Use of Proceeds - The company initially planned to raise 750 million yuan, which was intended for projects including the development of specialized electronic medical records (in emergency and maternal-child specialties), upgrades to comprehensive electronic medical records, data center upgrades, and to supplement working capital [1] - The total issuance costs for the IPO were 121 million yuan, with the lead underwriter, Huatai United Securities Co., Ltd., receiving 97.823 million yuan in underwriting fees [1]

证券代码：688246 证券简称：嘉和美康 嘉和美康（北京）科技股份有限公司 2025 年第五次临时股东会会议资料 2025 年 11 月 17 日 | 目 | 录 | | --- | --- | | 2025 年第五次临时股东会会议须知 | 2 | | 2025 年第五次临时股东会会议议程 | 4 | | 2025 年第五次临时股东会会议议案 | 6 | | 议案一：关于补选王清先生为公司第五届董事会董事的议案 | 6 | | 议案二：关于修订《公司章程》等十项制度的议案 | 7 | 1 嘉和美康（北京）科技股份有限公司 2025 年第五次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大 会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《公司章程》《股东会议事规则》等相关规定，特制定 嘉和美康（北京）科技股份有限公司（以下简称"公司"）2025 年第五次临时 股东会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大 ...

Core Viewpoint - 嘉和美康, a leading company in the domestic medical information industry, has faced challenges in its financial performance while actively investing in AI and product upgrades to enhance its competitive position [2][6]. Group 1: Company Overview - 嘉和美康 was established on March 3, 2006, and listed on the Shanghai Stock Exchange on December 14, 2021, with its headquarters in Beijing [1]. - The company specializes in the research and industrialization of medical information software and has maintained the highest market share in China's electronic medical records industry for 11 consecutive years [1]. Group 2: Financial Performance - For Q3 2025, 嘉和美康 reported revenue of 330 million yuan, ranking 60th among 102 companies in the industry, while the industry leader, 上海钢联, achieved revenue of 57.318 billion yuan [2]. - The net profit for the same period was -190 million yuan, placing the company 98th in the industry, with the top performer, 德赛西威, reporting a net profit of 1.805 billion yuan [2]. - The company's asset-liability ratio stood at 40.12%, higher than the industry average of 31.94%, and increased from 33.46% in the previous year [3]. - 嘉和美康's gross margin was 20.20%, significantly below the industry average of 41.71%, and down from 47.29% year-on-year [3]. Group 3: Shareholder Information - As of September 30, 2025, 嘉和美康 had 7,592 A-share shareholders, an increase of 1.84% from the previous period, with an average holding of 18,100 circulating A-shares, a decrease of 1.80% [5]. - The top ten circulating shareholders included 长城消费增值混合A, which held 2 million shares, down by 410,000 shares from the previous period [5]. Group 4: Management and Compensation - The chairman and general manager, 夏军, received a salary of 1.26 million yuan in 2024, an increase of 981,000 yuan from 2023 [4]. Group 5: Industry Outlook and Future Projections - 中泰证券 noted that while 嘉和美康's performance was under pressure in the first half of 2025, the medical information industry has significant growth potential, with the company actively expanding into the medical AI sector [5]. - The company plans to launch a smart clinical solution, C-Fusion 1.0, and is focused on upgrading its product system through increased R&D investment [5]. - 华泰证券 maintained its profit forecast for 嘉和美康, projecting net profits of 44 million, 102 million, and 191 million yuan for 2025 to 2027, respectively, and set a target price of 44.48 yuan [6].

Core Viewpoint - Jiahe Meikang (688246.SH) reported a significant decline in revenue and an increase in net loss for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters of 2025 was 330 million yuan, representing a year-on-year decrease of 30.67% [1] - The net profit attributable to shareholders of the parent company was -174 million yuan, which is a deterioration of 132 million yuan compared to the same period last year [1] - The basic earnings per share were -1.26 yuan [1]

Group 1 - The company Jiahe Meikang (SH 688246) announced the resignation of Wang Chunfeng from the position of employee representative director of the fifth board due to personal reasons, while she will continue to hold other positions within the company [1] - Ren Yong also plans to resign from the position of director of the fifth board due to internal work adjustments, but will retain other roles within the company [1] - The company has approved the election of Wang Qing as a candidate for the fifth board of directors and the election of Ren Yong as the employee representative director of the fifth board [1] Group 2 - For the fiscal year 2024, the revenue composition of Jiahe Meikang is projected to be 99.73% from the medical information industry and 0.27% from other industries [1] - As of the report date, the market capitalization of Jiahe Meikang is 3.3 billion yuan [1]

Core Insights - The company, Jiahe Meikang, reported a revenue of 330 million yuan for the first three quarters of 2025, with 110 million yuan generated in the third quarter [1] - The report highlights a strategic focus on internal growth and technological integration in response to significant industry changes driven by artificial intelligence and big data [1] Financial Performance - Total revenue for the first three quarters of 2025 reached 330 million yuan [1] - Revenue for the third quarter alone was 110 million yuan [1] Strategic Initiatives - The company is implementing a "clinical + data" dual-driven strategy to enhance its product competitiveness [1] - A new C-Fusion 1.0 intelligent integration clinical solution is being launched, which is based on a dual technology foundation of "domain-specific large models + general large models" [1] - The strategy aims to support the construction of smart hospitals by enabling comprehensive AI empowerment from clinical diagnosis to management [1]

嘉和美康（北京）科技股份有限公司 募集资金管理制度 嘉和美康（北京）科技股份有限公司（以下简称"公司"）为规范募集资金 的存放、使用和管理，保证募集资金的安全，最大限度地保障投资者的合法权益， 根据《中华人民共和国公司法》《上市公司治理准则》《上海证券交易所科创板股 票上市规则》（"以下简称《上市规则》"）和公司章程等规定，制定本制度。 第一章 总 则 第一条 本制度所称募集资金，是指公司通过向不特定对象发行证券（包括 首次公开发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换 公司债券等）以及向特定对象发行证券募集的资金，但不包括公司实施股权激励 计划募集的资金。 第二条 公司募集资金应当存放于经董事会批准设立的专项账户（以下简称 "募集资金专户"）集中管理和使用。募集资金专户不得存放非募集资金或用作 其它用途。 第三条 公司应当在募集资金到位后一个月内与保荐机构或者独立财务顾 问、存放募集资金的商业银行（以下简称"商业银行"）签订有关募集资金专户 存储三方监管协议（以下简称"协议"） 并及时公告。相关协议签订后，公司可 以使用募集资金。该协议至少应当包括以下内容： （一）公司应当将募集资金集中 ...